Use of HSP70 as a regulator of enzymatic activity
AssigneeZevra Denmark A/S
InventorsThomas Kirkegaard Jensen, Marja H. Jaattela
Life of this patent
Estimating the term…
Loading patent…
AssigneeZevra Denmark A/S
InventorsThomas Kirkegaard Jensen, Marja H. Jaattela
Estimating the term…
Lysosomal membrane permeabilization is an evolutionarily conserved hallmark of stress-induced cell death. Here the inventors show that the major stress-inducible heat shock protein 70 (Hsp70) enhances cell survival by stabilizing lysosomes through a pH-dependent high affinity binding to an endo-lysosomal anionic phospholipid bis(monoacylglycero)phosphate (BMP; also referred to as lysobisphosphatidic acid). The positively charged ATPase domain of Hsp70 is responsible for the binding but the substrate-binding domain is also required for effective stabilization of lysosomes. Importantly, the cytoprotective effect can be obtained by endocytic delivery of recombinant Hsp70 and specifically reverted by extra cellular administration of BMP antibodies or Hsp70 inhibitors. Thus, this protein-lipid interaction opens exciting possibilities for the development of cytoprotective and cytotoxic lysosome-specific therapies for the treatment of degenerative diseases and cancer, respectively.
A method for treating a lysosomal storage disorder by increasing the intracellular concentration and/or activity of Hsp70 by administering to a human patient in need thereof a pharmaceutically effective amount of an Hsp70 gene expression amplifying bioactive agent, wherein the bioactive agent is a cyclooxygenase 1/2 inhibitor,
Dependencies are inferred from the claim text.